T0	Participants 115 135	early breast cancer:
T1	Participants 281 287	women.
T2	Participants 502 528	1,614 consecutive patients
T3	Participants 621 693	postmenopausal women with early hormone receptor-positive breast cancer.
T4	Participants 1268 1296	Patients receiving tamoxifen